Affordable Access

deepdyve-link
Publisher Website

[Meningioma: management of the most common brain tumour].

Authors
  • Hundsberger, Thomas1, 2
  • Surbeck, Werner3
  • Hader, Claudia4
  • Putora, Paul Martin5
  • Conen, Katrin6
  • Roelcke, Ulrich7
  • 1 1 Klinik für Neurologie, Kantonsspital St. Gallen.
  • 2 2 Klinik für Hämatologie und Onkologie, Kantonsspital St. Gallen.
  • 3 3 Klinik für Neurochirurgie, Kantonsspital St. Gallen.
  • 4 4 Klinik für Radiologie und Nuklearmedizin, Kantonsspital St. Gallen.
  • 5 5 Klinik für Radioonkologie, Kantonsspital St. Gallen.
  • 6 6 Klinik für Onkologie, Universitätsspital Basel.
  • 7 7 Neurologische Klinik und Hirntumorzentrum, Kantonsspital Aarau.
Type
Published Article
Journal
Praxis
Publication Date
Apr 13, 2016
Volume
105
Issue
8
Pages
445–451
Identifiers
DOI: 10.1024/1661-8157/a002320
PMID: 27078728
Source
Medline
Keywords
License
Unknown

Abstract

Meningiomas are the most common primary brain tumours in adults and are therefore relevant for general practitioners. Most meningiomas are benign and neurosurgical resection offers the best chance of cure. However, complete resection is not achievable in many patients. This accounts for a relevant rate of tumour recurrences within 15 years of follow up. In atypical and anaplastic meningiomas of WHO grade II and III time to recurrence is dramatically shorter and these tumours need multimodal treatment strategies including postoperative radiotherapy. Various systemic treatments have occasionally been used as salvage therapy, but were essentially not effective. Only recently, Sunitinib, a small thyrosine kinase inhibitor as well as bevacizumab, a therapeutic antibody, have shown more promising results in highly pretreated, refractory meningioma patients.

Report this publication

Statistics

Seen <100 times